Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.0404 EUR
−6.82 M EUR
47.03 M EUR
6.10 M
About Champions Oncology, Inc.
Sector
Industry
CEO
Ronnie Morris
Website
Headquarters
Hackensack
Founded
1985
FIGI
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on LSX exchange Champions Oncology, Inc. stocks are traded under the ticker A14X6S.
A14X6S stock hasn't changed in a week, the last month showed zero change in price, over the last year there was no change in Champions Oncology, Inc. price.
We've gathered analysts' opinions on Champions Oncology, Inc. future price: according to them, A14X6S price has a max estimate of 7.64 EUR and a min estimate of 7.64 EUR. Watch A14X6S chart and read a more detailed Champions Oncology, Inc. stock forecast: see what analysts think of Champions Oncology, Inc. and suggest that you do with its stocks.
A14X6S stock is 0.00% volatile and has beta coefficient of 0.12. Track Champions Oncology, Inc. stock price on the chart and check out the list of the most volatile stocks — is Champions Oncology, Inc. there?
Yes, you can track Champions Oncology, Inc. financials in yearly and quarterly reports right on TradingView.
Champions Oncology, Inc. is going to release the next earnings report on Mar 18, 2025. Keep track of upcoming events with our Earnings Calendar.
A14X6S earnings for the last quarter are 0.05 EUR per share, whereas the estimation was 0.01 EUR resulting in a 400.00% surprise. The estimated earnings for the next quarter are −0.01 EUR per share. See more details about Champions Oncology, Inc. earnings.
Champions Oncology, Inc. revenue for the last quarter amounts to 12.41 M EUR, despite the estimated figure of 12.00 M EUR. In the next quarter, revenue is expected to reach 12.54 M EUR.
A14X6S net income for the last quarter is 668.96 K EUR, while the quarter before that showed 1.21 M EUR of net income which accounts for −44.84% change. Track more Champions Oncology, Inc. financial stats to get the full picture.
No, A14X6S doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 16, 2025, the company has 210.00 employees. See our rating of the largest employees — is Champions Oncology, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Champions Oncology, Inc. EBITDA is 1.58 M EUR, and current EBITDA margin is −10.08%. See more stats in Champions Oncology, Inc. financial statements.
Like other stocks, A14X6S shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Champions Oncology, Inc. stock right from TradingView charts — choose your broker and connect to your account.